FDA spells out 2027 AI guidance plans

The FDA has outlined plans to issue new artificial intelligence guidances in 2027, according to STAT News’s Health Tech newsletter, published October 6. The report, part of STAT+’s subscriber coverage, frames the forthcoming guidances as part of a broader regulatory effort to establish formal frameworks for how AI tools are developed and deployed in medicine.

The same dispatch notes that Utah is expanding its state-level AI sandbox program, a regulatory mechanism that allows companies to test AI applications, including health-related ones, under relaxed oversight conditions before full compliance requirements apply.

STAT’s summary indicates the newsletter edition covers additional health-tech developments beyond these two items, though specifics beyond the FDA timeline and the Utah sandbox expansion were not detailed in the available material.

The timing of the FDA’s 2027 guidance plans follows several years of agency statements on AI oversight in medical devices and software, an area regulators have approached incrementally as the technology’s use in diagnostics, clinical decision support, and administrative systems has grown. The STAT report does not specify which categories of AI tools the 2027 guidances will address, nor does it detail the regulatory mechanisms under consideration.

No further particulars on either the FDA timeline or the Utah program were available in the cited material at time of publication.